Candriam SCA’s MacroGenics MGNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-198,043
Closed -$685K 881
2022
Q3
$685K Sell
198,043
-319,549
-62% -$1.22M ﹤0.01% 781
2022
Q2
$1.53M Hold
517,592
0.01% 556
2022
Q1
$4.56M Sell
517,592
-30,137
-6% -$333K 0.03% 366
2021
Q4
$8.79M Sell
547,729
-60,794
-10% -$1.14M 0.06% 283
2021
Q3
$12.7M Hold
608,523
0.09% 234
2021
Q2
$16.3M Sell
608,523
-67,607
-10% -$1.98M 0.11% 215
2021
Q1
$14.8M Buy
676,130
+5
+0% +$121 0.12% 184
2020
Q4
$15.5M Buy
676,125
+94,271
+16% +$2.17M 0.12% 186
2020
Q3
$14.7M Buy
581,854
+113,421
+24% +$3.1M 0.14% 176
2020
Q2
$13.1M Sell
468,433
-279,330
-37% -$4.85M 0.14% 172
2020
Q1
$7.95M Hold
747,763
0.09% 258
2019
Q4
$8.14M Sell
747,763
-7,225
-1% -$71.5K 0.09% 262
2019
Q3
$9.63M Buy
754,988
+4,000
+0.5% +$57.6K 0.13% 191
2019
Q2
$12.7M Buy
750,988
+85,500
+13% +$1.47M 0.16% 152
2019
Q1
$12M Buy
665,488
+122,501
+23% +$2.12M 0.15% 156
2018
Q4
$6.9M Buy
542,987
+186,387
+52% +$3.13M 0.11% 222
2018
Q3
$7.65M Buy
356,600
+265,000
+289% +$5.65M 0.1% 233
2018
Q2
$1.89M Buy
91,600
+16,600
+22% +$374K 0.03% 499
2018
Q1
$1.89M Hold
75,000
0.03% 491
2017
Q4
$1.43M Buy
+75,000
New +$1.4M 0.02% 517
2017
Q1
Sell
-60,000
Closed -$1.23M 703
2016
Q4
$1.23M Sell
60,000
-50,000
-45% -$1.26M 0.03% 479
2016
Q3
$3.29M Sell
110,000
-39,500
-26% -$1.17M 0.08% 269
2016
Q2
$4.04M Buy
149,500
+31,500
+27% +$710K 0.1% 215
2016
Q1
$2.2M Sell
118,000
-17,100
-13% -$326K 0.06% 307
2015
Q4
$4.18M Buy
135,100
+29,000
+27% +$881K 0.11% 199
2015
Q3
$2.27M Sell
106,100
-27,900
-21% -$875K 0.06% 319
2015
Q2
$5.09M Sell
134,000
-91,000
-40% -$2.99M 0.11% 238
2015
Q1
$7.06M Hold
225,000
0.14% 192
2014
Q4
$7.89M Buy
+225,000
New +$5.61M 0.17% 177

Other funds holding MGNX

Candriam SCA's MGNX Position: Q4 2022 in Review

Candriam SCA sold out of MacroGenics (MGNX) in Q4 2022, closing a stake of 198,043 shares — an estimated $685K sold.

Candriam SCA first reported a position in MGNX in Q4 2014 and held it in 29 quarters. The position peaked at $16.3M in Q2 2021. 135 funds tracked by Wall St. Rank hold MGNX as of Q4 2022.

  • Candriam SCA reported no remaining MacroGenics position as of Q4 2022 after selling out during the quarter.
  • Candriam SCA sold 198,043 MacroGenics shares in Q4 2022, an estimated $685K.
  • Candriam SCA first reported a position in MacroGenics in Q4 2014 and held it in 29 quarters.
  • Candriam SCA's MacroGenics position peaked at $16.3M in Q2 2021.
  • 135 funds tracked by Wall St. Rank held MacroGenics as of Q4 2022.

Based on Candriam SCA's 13F filing for Q4 2022, filed 13 Feb 2023.